Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic colorectal cancer by assessing progression-free survival.

Trial Details

NCT ID
NCT06425133
Phase
PHASE2
Sponsor
Centre Hospitalier Universitaire de Besancon
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Blood sample
  • Quality of life questionnaires
  • Biopsy
  • Regorafenib
  • Regorafenib + metronomic chemotherapy
Locations (sample)
  • Auxerre, France|47.7996,3.57033
  • Besançon, France|47.24878,6.01815
  • Colmar, France|48.08078,7.35584
  • Dijon, France|47.31344,5.01391
  • Metz, France|49.11911,6.17269

Key Eligibility Criteria

  • Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11 (Irinotecan), oxalip…
  • Life expectancy of at least 3 months
  • Female or male with age \>18 years old
  • Performance status = 0 or 1 (Annex 1)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →